NUTRI's Production Capacity Expansion and Increased Sales in the Smile Care Business
First written in FY2016. 4 of 15 entries say "Restated". Latest entry: FY2021-Q3.
No other company in this theme has enough history to compare yet.
- FY2021-Q3RestatedAnnual report
「ニュートリー㈱ also posted higher profit as improvements in selling, general and administrative expenses paid off.」
ニュートリー posted lower revenue due to the impact of the spread of COVID-19, but higher profit from improved selling, general and administrative expenses. - FY2021-Q2Higher profit despite lower revenue from curbs on sales activities, due to improved selling, general and administrative expensesAnnual report
「ニュートリー㈱ posted lower revenue because the impact of COVID-19 forced it to curb sales activities, but profit increased partly due to improved selling, general and administrative expenses.」
At ニュートリー, sales activities were curtailed due to the impact of the infectious disease, resulting in lower revenue, while improved selling, general and administrative expenses led to higher profit. - FY2021-Q1Higher profit despite lower revenue from curbs on sales activities, due to lower operating expensesAnnual report
「ニュートリー㈱ posted lower revenue because the spread of COVID-19 forced it to curb active sales activities such as seminars and new-product sampling, but profit increased partly due to lower operating expenses.」
At ニュートリー, the spread of the infection led it to curb seminars and new-product sampling, resulting in lower revenue, while lower operating expenses led to higher profit. - FY2020-Q3Higher revenue and higher profit due to increased sales of the enteral nutrition business and other operationsAnnual report
「ニュートリー㈱ posted higher revenue and higher profit due to increased sales of the enteral nutrition business and other operations acquired at the beginning of the fiscal year.」
After acquiring the enteral nutrition business and other operations, ニュートリー posted higher revenue and higher profit on increased sales, improving from the lower-profit trend through the previous quarter. - FY2020-Q1Higher revenue from the acquisition of the enteral nutrition business, but lower profit due to higher miscellaneous expensesAnnual report
「ニュートリー㈱ posted higher revenue from the enteral nutrition business acquired at the beginning of the fiscal year, but profit declined due to higher miscellaneous expenses.」
ニュートリー posted higher revenue from the newly acquired enteral nutrition business, but profit declined due to higher miscellaneous expenses. - FY2019ニュートリー's lower revenue and lower profit, and lower profit at タイショーテクノス due to one-time expensesAnnual report
「In addition to lower sales at ニュートリー㈱, higher personnel, transportation and other expenses to strengthen the sales organization resulted in lower revenue and lower profit. Although ㈱タイショーテクノス posted higher revenue, its profit declined due to one-time expenses associated with the construction of a new plant and research and development facility.」
ニュートリー posted lower revenue and lower profit after expanding its business, due to lower sales and higher selling and transportation expenses, while タイショーテクノス also posted lower profit due to one-time expenses for a new plant and other facilities. - FY2019-Q3Lower revenue and lower profit due to weak sales of some products in the acquired business and costs to strengthen the sales organizationAnnual report
「ニュートリー㈱ posted lower revenue and lower profit because some products in the business acquired in the previous fiscal year saw weak sales, while personnel expenses and other costs increased to strengthen the sales organization.」
ニュートリー posted lower revenue and lower profit due to weak sales of some products in the acquired business, as well as higher personnel expenses and other costs associated with strengthening the sales organization. - FY2019-Q2Lower revenue and lower profit due to weaker sales of the acquired business and higher personnel expensesAnnual report
「In addition to lower sales of the business acquired by ニュートリー㈱ in the previous fiscal year, higher personnel expenses resulted in lower revenue and lower profit.」
ニュートリー posted lower revenue and lower profit due to lower sales of the business acquired in the previous fiscal year and higher personnel expenses. - FY2019-Q1Weak sales of the acquired businessAnnual report
「Among the consolidated subsidiaries, although sales at ㈱タイショーテクノス were solid, sales of the business acquired by ニュートリー㈱ in the previous fiscal year remained weak.」
At ニュートリー, sales of the business acquired in the previous fiscal year remained weak, indicating weakness in the earnings contribution from its business expansion initiatives. - FY2018-Q3RestatedAnnual report
「Among the consolidated subsidiaries, ㈱タイショーテクノス saw sales volume increase, while ニュートリー㈱ expanded in scale through the business acquisition conducted at the beginning of the fiscal year, resulting in higher revenue and higher profit.」
ニュートリー continued to expand in scale and post higher revenue and higher profit after the business acquisition at the beginning of the fiscal year. - FY2017AdvancedAnnual report
「ニュートリー㈱ will make full use of facilities that have tripled its production capacity and will continue to strengthen its presence in the medical and nursing-care food sector, where demand is expected to expand. It will also rapidly integrate the nutrition business acquired from ㈱三和化学研究所 on 1 April 2017 and work to strengthen its business platform.」
ニュートリー's facilities, with production capacity tripled, entered the full-scale utilization phase, advancing expansion in the medical and nursing-care food sector and integration of the acquired business. - FY2017-Q3RestatedAnnual report
「Both consolidated subsidiaries, ㈱タイショーテクノス and ニュートリー㈱, saw sales remain strong, but posted higher revenue and lower profit year on year due to upfront investment associated with business expansion and other factors.」
This reconfirms the food science subsidiaries' strong sales and higher revenue but lower profit due to upfront investment associated with business expansion. - FY2017-Q2RestatedAnnual report
「Both consolidated subsidiaries, ㈱タイショーテクノス and ニュートリー㈱, saw sales remain strong, but posted higher revenue and lower profit year on year due to upfront investment associated with business expansion and other factors.」
Food science subsidiaries continued to see strong sales, but posted higher revenue and lower profit due to upfront investment associated with business expansion. - FY2017-Q1Profit declined as expenses increased along with higher sales.Annual report
「At the consolidated subsidiaries, sales of purchased products at ㈱タイショーテクノス were strong but were affected by soaring raw material costs, while ニュートリー㈱ increased sales but also incurred higher operating expenses. As a result, profit declined year on year.」
ニュートリー saw sales grow, but profit declined year on year due to higher operating expenses and other factors. - FY2016First statedAnnual report
「The consolidated subsidiary ニュートリー㈱ is currently making capital investments to triple its production capacity. Against the backdrop of favorable conditions in the institutional food industry, including the government's measures to revitalize the medical, nursing care and healthcare industries, the Company will pursue expanded domestic sales in the Smile Care field.」
The Company plans to triple ニュートリー's production capacity and expand domestic sales in the Smile Care field of the institutional food business.